Clinical and Immunohistochemical Analysis of Patients with Unknown Primary Tumour. A Search for Prognostic Factors in UPT

Anticancer Research

Volumn 24, Issue 1, 2004, Pages 297-301

  Van De Wouw, Agnès J ^a,b   Jansen, Rob L H ^a   Griffioen, Arjan W ^a   Hillen, Harry F P ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SLINGELAND HOSPITAL   (Netherlands)

Author keywords

Adenocarcinoma; Prognostic factors; UPT

Indexed keywords

CD34 ANTIGEN; CD44V6 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; PROTEIN P53; VASCULOTROPIN A;

ADENOCARCINOMA; ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OCCULT CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; SCORING SYSTEM; UNKNOWN PRIMARY TUMOR;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD34; ANTIGENS, CD44; FEMALE; GLYCOPROTEINS; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 1442350528     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hillen HF: Unknown primary tumours. Postgrad Med J 76(901): 690-3, 2000.
2. Lembersky BC and Thomas LC: Metastases of unknown primary site. Med Clin North Am 80(1): 153-71, 1996.
3. Greco FA and Hainsworth JD: Cancer of unknown primary site. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology. edit 6, 2072-2092. 2000. Philadelphia PA Lippincott.
4. van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW and Hillen HF: Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 38(3): 409-13, 2002.
5. Nystrom JS, Weiner JM, Heffelfinger-Juttner J, Irwin LE, Bateman JR and Wolf RM: Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 4(1): 53-8, 1977.
6. Le Chevalier T, Cvitkovic E, Caille P, Harvey J, Contesso G, Spielmann M and Rouesse J: Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med 148(9): 2035-9, 1988.
7. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R and Frost P: Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12(6): 1272-80, 1994.
8. Altman E and Cadman E: An analysis of 1539 patients with cancer of unknown primary site. Cancer 57(1): 120-4, 1986.
9. van de Wouw AJ, Jansen RL, Speel EJ and Hillen HF: The unknown biology of the unknown primary tumour: a literature review. Ann Oncol 14(2): 191-6, 2003.
10. Hainsworth JD, Lennington WJ and Greco FA: Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 18(3): 632-5, 2000.
11. Bonnefoi H, Diebold-Berger S, Therasse P et al: Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol 14(3): 406-13, 2003.
12. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P and Norton L: P53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 13(4): 821-30, 1995.
13. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H and Herrlich, P: CD44 isoforms in prognosis of breast cancer. Lancet 346(8973): 502, 1995.
14. Friedrichs K, Franke F, Lisboa BW, Kugler G, Gille I, Terpe HJ, Holzel F, Maass H and Gunthert U: CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 55(22): 5424-33, 1995.
15. Gasparini G, Toi M, Gion M, Verderio P et al: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89(2): 139-47, 1997.
16. Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y and Hirohashi S: Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 6(6): 2431-9, 2000.
17. Vermeulen PB, Gasparini G, Fox SB et al: Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A (14): 2474-84, 1996.
18. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P and Norton L: Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis. Cancer 75(6): 1320-6, 1995.
19. Hainsworth JD and Greco FA: Management of patients with cancer of unknown primary site. Oncology (Huntingt) 14(4): 563-74, 2000.
20. Hainsworth JD, Burris HA, Calvert SW, Willcutt NT, Scullin DC, Bramham J and Greco FA: Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest 19(4): 335-9, 2001.
21. Greco FA, Burris HA, Litchy S et al: Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 20(6): 1651-6, 2002.
22. Greco FA, Erland JB, Morrissey LH, Burris HA, Hermann RC, Steis R, Thompson D, Gray J and Hainsworth JD: Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 11(2): 211-5, 2000.
23. van der Gaast A, Verweij J, Planting AS and Stoter G: 5-Fluorouracil, doxorubicin and mitomycin C: (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary. Eur J Cancer Clin Oncol 24(4): 765-8, 1988.
24. Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A and Fizazi K: Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20(24): 4679-83, 2002.
25. Gilbert HA and Kagan AR: Metastases: incidence, detection, and evaluation without histologic confirmation. Pp. 385-405. In: Weiss.L., ed.Fundamental Aspects of Metastasis. Amsterdam, North-Holland, 1976.QZ.200.W9264f.1975.
26. Abrams HL, Spiro R and Goldstein N: Metastases in carcinoma: analysis of 1000 autopsied cases. Cancer 3: 74-85, 1950.
27. Bar-Eli M, Abbruzzese JL, Lee-Jackson D and Frost P: P53 gene mutation spectrum in human unknown primary tumors. Anticancer Res 13(5A): 1619-23, 1993.
28. Briasoulis E, Tsokos M, Fountzilas G, Bafaloukos D, Kosmidis P, Samantas E, Skarlos D, Nicolaides C and Pavlidis N: Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co- Operative Oncology Group Study. Anticancer Res 18(3B): 1907-14, 1998.
29. Hillen HF, Hak LE, Joosten-Achjanie SR and Arends JW: Microvessel density in unknown primary tumors. Int J Cancer 74(1): 81-5, 1997.